Clinical Trials
25 trialsPhase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
Reveal Pharmaceuticals Inc.
CBT-I in PBT
Virginia Commonwealth University
Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers
National Institutes of Health Clinical Center (CC)
Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas System
Cedars-Sinai Medical Center
Observation or Radiation Therapy in Treating Patients With Grade I, Grade II, or Grade III Meningioma
Radiation Therapy Oncology Group
CEVOREM
Assistance Publique Hopitaux De Marseille
Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
University of Iowa
AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas
Massachusetts General Hospital
Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors
Wake Forest University Health Sciences
Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor
Wake Forest University Health Sciences
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
National Institutes of Health Clinical Center (CC)
Hydroxyurea in Treating Patients With Recurrent and/or Unresectable Meningioma
UNICANCER
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
Northwestern University
Vatalanib in Treating Patients With Recurrent or Progressive Meningioma
Northwestern University
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Monthly SOM230C for Recurrent or Progressive Meningioma
Dana-Farber Cancer Institute
Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2
NYU Langone Health
Imatinib Mesylate in Treating Patients With Recurrent Meningioma
National Cancer Institute (NCI)
Combination of Hydroxyurea and Verapamil for Refractory Meningiomas
University of Utah
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
SWOG Cancer Research Network
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
Memorial Sloan Kettering Cancer Center
Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer
National Cancer Institute (NCI)
Levetiracetam or Pregabalin in Treating Seizures in Patients Undergoing Chemotherapy and/or Radiation Therapy For Primary Brain Tumors
Centre Hospitalier Universitaire Vaudois
Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer
Barbara Ann Karmanos Cancer Institute
Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma
Duke University